Aspirin insensitive thrombophilia: Transcript profiling of blood identifies platelet abnormalities and HLA restriction

Gene

Volumn 520, Issue 2, 2013, Pages 131-138

  Fallahi, Payam ^a   Katz, Richard ^a   Toma, Ian ^a   Li, Ranyang ^a   Reiner, Jonathan ^a   VanHouten, Kiersten ^a   Carpio, Larry ^a   Marshall, Lorraine ^a   Lian, Yi ^a   Bupp, Sujata ^a   Fu, Sidney W ^a   Rickles, Frederick ^a   Leitenberg, David ^a   Lai, Yinglei ^a   Weksler, Babette B ^b   Rebling, Frederik ^a   Yang, Zhaoqing ^a   McCaffrey, Timothy A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aspirin; Coagulation; Genetics; Platelets; Thrombosis; Transcript profiling

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; AUTOANTIBODY; CLUSTERIN; FIBRINOGEN RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DQA1 ANTIGEN; HLA DRB4 ANTIGEN; LACTOFERRIN; LIPOCALIN; PHOSPHOLIPID; PLECKSTRIN; THROMBOPOIETIN RECEPTOR;

ARTICLE; ASPIRIN INSENSITIVE THROMBOPHILIA; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HLA SYSTEM; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; TH1 CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOPHILIA;

ASPIRIN; BLOOD; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; HISTOCOMPATIBILITY TESTING; HLA-DQ ALPHA-CHAINS; HLA-DRB4 CHAINS; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RNA, MESSENGER; THROMBOPHILIA;

EID: 84876323694     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.02.032     Document Type: Article

References (51)

1. Baig A., Bao X., Wolf M., Haslam R.J. The platelet protein kinase C substrate pleckstrin binds directly to SDPR protein. Platelets 2009, 20:446-457.
2. Baigent C. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
3. Bauer J.W., et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009, 60:3098-3107.
4. Bernales I., et al. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun. 2008, 9:38-46.
5. Bertolaccini M.L., et al. Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum. 2000, 43:683-688.
6. Biondi-Zoccai G.G., et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur. Heart J. 2006, 27:2667-2674.
7. Bykowska K., Pawlowska Z., Cierniewski C., Lopaciuk S., Kopec M. Different effects of human neutrophil elastase on platelet glycoproteins IIb and IIIa of resting and stimulated platelets. Thromb. Haemost. 1990, 64:69-73.
8. Cahan P., et al. List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists. Gene 2005, 360:78-82.
9. Caliz R., et al. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford) 2001, 40:31-36.
10. Catella-Lawson F., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 2001, 345:1809-1817.
11. Chu J.W., Wong C.K., Chambers J., Wout J.V., Herbison P., Tang E.W. Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. QJM 2010, 103:405-412.
12. Coleman J. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point Care 2004, 3:6.
13. Colucci A.T., et al. Blood antiphospholipid antibody levels are influenced by age, sex and HLA-B8, DR3 phenotype. Exp. Clin. Immunogenet. 1992, 9:72-79.
14. Del Castillo-Carnevali H.A., Alonso V.B., Saban-Ruiz J., Gomez J.L. Poor response to antiplatelet drugs. An Important Issue in Drug- Eluting Stents. Curr. Clin. Pharmacol. 2012, (Epub ahead of print).
15. Fitzgerald R., Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol. Ther. 2011, 130:213-225.
16. Fontana P., et al. Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thromb. Haemost. 2006, 96:356-360.
17. Fujiwara T., et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J. 2007, 7:395-403.
18. Glauser J., Emerman C.L., Bhatt D.L., Peacock W.F.t. Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. Am. J. Emerg. Med. 2010, 28:440-444.
19. Gnatenko D.V., Dunn J.J., McCorkle S.R., Weissmann D., Perrotta P.L., Bahou W.F. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003, 101:2285-2293.
20. Gu D., et al. Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Hum. Immunol. 2010, 71:586-591.
21. Gurbel P.A., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 2005, 46:1820-1826.
22. Guthikonda S., et al. Increased platelet sensitivity among individuals with aspirin resistance-platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb. Haemost. 2008, 100:83-89.
23. Hayakawa T., Jin C.X., Ko S.B., Kitagawa M., Ishiguro H. Lactoferrin in gastrointestinal disease. Intern. Med. 2009, 48:1251-1254.
24. Horikawa Y., et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997, 90:4031-4038.
25. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
26. Joseph J.E., Donohoe S., Harrison P., Mackie I.J., Machin S.J. Platelet activation and turnover in the primary antiphospholipid syndrome. Lupus 1998, 7:333-340.
27. Kapitany A., et al. Human leukocyte antigen-DRB1 and -DQB1 genotyping in lupus patients with and without antiphospholipid syndrome. Ann. N. Y. Acad. Sci. 2009, 1173:545-551.
28. Kubota Y., et al. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 1996, 14:439-444.
29. Leveugle B., Mazurier J., Legrand D., Mazurier C., Montreuil J., Spik G. Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. Eur. J. Biochem. 1993, 213:1205-1211.
30. Levy-Toledano S., Grelac F., Caen J.P., Maclouf J. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism. Thromb. Haemost. 1995, 73:857-861.
31. Lian L., et al. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood 2009, 113:3577-3584.
32. Linden M.D., Tran H., Woods R., Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin. Thromb. Hemost. 2012, 38:200-212.
33. Lupia E., et al. Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina. J. Am. Coll. Cardiol. 2006, 48:2195-2203.
34. Mattiello T., et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J. Am. Coll. Cardiol. 2011, 58:752-761.
35. McIntyre J.A., Wagenknech D.R., Waxman D.W. Frequency and specificities of antiphospholipid antibodies (aPL) in volunteer blood donors. Immunobiology 2003, 207:59-63.
36. McIntyre J.A., Wagenknecht D.R., Faulk W.P. Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog. Lipid Res. 2003, 42:176-237.
37. Michalowska-Wender G., Losy J., Szczucinski A., Biernacka-Lukanty J., Wender M. Effect of methylprednisolone treatment on expression of sPECAM-1 and CXCL10 chemokine in serum of MS patients. Pharmacol. Rep. 2006, 58:920-923.
38. Palikhe N.S., Kim S.H., Lee H.Y., Kim J.H., Ye Y.M., Park H.S. Association of thromboxane A2 receptor (TBXA2R) gene polymorphism in patients with aspirin-intolerant acute urticaria. Clin. Exp. Allergy 2011, 41:179-185.
39. Rocca B., Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012, 2012:376721.
40. Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Autoimmun. Rev. 2009, 9:90-92.
41. Shen H., et al. Aspirin resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am. J. Cardiol. 2009, 104:606-612.
42. Si-Tahar M., et al. Human neutrophil elastase proteolytically activates the platelet integrin alphaIIbbeta3 through cleavage of the carboxyl terminus of the alphaIIb subunit heavy chain. Involvement in the potentiation of platelet aggregation. J. Biol. Chem. 1997, 272:11636-11647.
43. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 2007, 167:1593-1599.
44. Su G., Wang Z., Ding Y. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J. Huazhong Univ. Sci. Technol. Med. Sci. 2007, 27:664-667.
45. Sweeny J., Gorog D., Fuster V. Antiplatelet drug 'resistance'/Part 1: mechanisms and clinical measurements. Nat. Rev. Cardiol. 2009, 6:273-282.
46. Thon J.N., Devine D.V. Translation of glycoprotein IIIa in stored blood platelets. Transfusion 2007, 47:2260-2270.
47. Uthman I., Godeau B., Taher A., Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008, 22:187-194.
48. Weber A.A., Przytulski B., Schanz A., Hohlfeld T., Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002, 13:37-40.
49. Yu M., Cantor A.B. Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers. Methods Mol. Biol. 2012, 788:291-303.
50. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345:494-502.
51. Zhang H., et al. Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J. Cell. Biochem. 2011, 112:1832-1843.